Olanzapine-induced weight gain in patients with bipolar I disorder: A meta-analysis

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 6, 2011, Pages

  Nashed, Mina G ^a   Restivo, Maria R ^a   Taylor, Valerie H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASENAPINE; HALOPERIDOL; LITHIUM CARBONATE; OLANZAPINE; PLACEBO; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ADVERSE OUTCOME; BIPOLAR I DISORDER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN;

EID: 84856065166     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11r01174     Document Type: Review

References (43)

1. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225-255. PubMed doi:10.1111/j.1399-5618.2009.00672.x
2. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64(4):442-455. PubMed doi:10.1001/archpsyc.64.4.442
3. Liauw SS, McIntyre RS. Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother. 2010;11(17):2827-2837. PubMed doi:10.1517/14656566.2010.510835
4. Cascade EF, Kalali AH, Lieberman J, et al. Use of antipsychotics pre-and post-dissemination of CATIE data. Psychiatry (Edgmont). 2007;4(5):21-23. PubMed
5. Symbyax Approval Letter. (NDA 21-520), Department of Health and Human Services. Food and Drug Administration, 12-24-2003. www.accessdata.fda.gov/drugsatfda_docs/appletter/2003/21520ltr.pdf. Accessed October 3, 2011.
6. Zyprexa Approval Letter. (NDA 20-592/S-019), Department of Health and Human Services. Food and Drug Administration, 01-14-2004. www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/20592se1-019ltr.pdf. Accessed October 3, 2011.
7. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. PubMed doi:10.1016/S0140-6736(08)61764-X
8. Komossa K, Rummel-Kluge C, Hunger H, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654. PubMed
9. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2-3):225-233. PubMed doi:10.1016/j.schres.2010.07.012
10. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162(7):1281-1290. PubMed doi:10.1176/appi.ajp.162.7.1281
11. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247-256. PubMed doi:10.1176/appi.ajp.163.2.247
12. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59(1):7-10. PubMed doi:10.1016/j.jclinepi.2005.06.006
13. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0. The Cochrane Collaboration, 2011. www.cochrane-handbook.org. Accessed October 3, 2011.
14. Streiner DL. Meta-analysis. PowerPoint presentation presented at the Department of Psychiatry, University of Toronto; September 21, 2010; Toronto, Ontario, Canada.
15. Tohen M, Sanger TM, McElroy SL, et al; Olanzapine HGEH Study Group. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156(5):702-709. PubMed
16. Tohen M, Jacobs TG, Grundy SL, et al; The Olanzipine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57(9):841-849. PubMed doi:10.1001/archpsyc.57.9.841
17. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-1088. PubMed doi:10.1001/archpsyc.60.11.1079
18. Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry. 2008;69(11):1776-1789. PubMed doi:10.4088/JCP.v69n1113
19. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12):1218-1226. PubMed doi:10.1001/archpsyc.60.12.1218
20. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;63(12):1148-1155. PubMed doi:10.4088/JCP.v63n1210
21. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003c;160(7):1263-1271. PubMed doi:10.1176/appi.ajp.160.7.1263
22. Kim B, Kim SJ, Son JI, et al. Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord. 2008;105(1-3):45-52. PubMed doi:10.1016/j.jad.2007.04.006
23. Novick D, Gonzalez-Pinto A, Haro JM, et al; EMBLEM Advisory Board. Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. Pharmacopsychiatry. 2009;42(4):145-152. PubMed doi:10.1055/s-0028-1128115
24. Niufan G, Tohen M, Qiuqing A, et al. Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial. J Affect Disord. 2008;105(1-3):101-108. PubMed doi:10.1016/j.jad.2007.04.020
25. Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006;67(11):1747-1753. PubMed doi:10.4088/JCP.v67n1112
26. Novick D, Reed C, Haro JM, et al. Comparison of olanzapine and risperidone in the EMBLEM study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010;25(5):257-263. PubMed doi:10.1097/YIC.0b013e32833b8fe4
27. McIntyre RS, Cohen M, Zhao J, et al. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009;11(8):815-826. PubMed doi:10.1111/j.1399-5618.2009.00749.x
28. Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762-1784. PubMed doi:10.1111/j.1742-1241.2009.02228.x
29. Vieta E, Bourin M, Sanchez R, et al; Aripiprazole Study Group. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187(3):235-242. PubMed doi:10.1192/bjp.187.3.235
30. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain. J Clin Psychiatry. 2003;64(12):1426-1435. PubMed doi:10.4088/JCP.v64n1205
31. Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4-18. PubMed doi:10.1111/j.1600-0447.2008.01204.x
32. Treuer T, Hoffmann VP, Chen AK, et al. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry. 2009;10(4, Pt 3):729-740. PubMed doi:10.1080/15622970903079507
33. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. PubMed doi:10.1056/NEJMoa051688
34. Velligan DI, Weiden PJ, Sajatovic M, et al; Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. The Expert Consensus Guideline Series: Adherence Problems in Patients With Serious and Persistent Mental Illness. J Clin Psychiatry. 2009;70(suppl 4):1-46, quiz 47-48. PubMed
35. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480-491. PubMed
36. Soczynska JK, Kennedy SH, Woldeyohannes HO, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med. 2011;13(2):93-116. PubMed doi:10.1007/s12017-010-8140-8
37. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57(8):1140-1144. PubMed doi:10.1176/appi.ps.57.8.1140
38. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100. PubMed doi:10.4088/JCP.v62n0204
39. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 2001;62(suppl 2):41-44. PubMed
40. Praharaj SK, Jana AK, Goyal N, et al. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011;71(3):377-382. PubMed doi:10.1111/j.1365-2125.2010.03783.x
41. Narula PK, Rehan HS, Unni KE, et al. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res. 2010;118(1-3):218-223. PubMed doi:10.1016/j.schres.2010.02.001
42. Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Schizophr Res. 2007;91(1-3):169-177. PubMed doi:10.1016/j.schres.2006.12.025
43. Kwon JS, Choi JS, Bahk WM, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial. J Clin Psychiatry. 2006;67(4):547-553. PubMed doi:10.4088/JCP.v67n0405